Novel Neuroprotective Multicomponent Therapy for Amyotrophic Lateral Sclerosis Designed by Networked Systems

Area of Science:

• Neuroscience
• Pharmacology
• Computational Biology

Background:

• Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease with no effective treatments.
• Multiple pathological mechanisms contribute to motor neuron death in ALS.
• A holistic approach is needed to target these diverse pathways.

Purpose of the Study:

• To identify novel drug combinations for ALS using a systems biology approach.
• To investigate polypharmacology for targeting multiple etiopathogenic pathways in ALS.
• To validate the neuroprotective potential of identified drug combinations in vitro.

Main Methods:

• Utilized a systems biology approach with Repositioning Analysis (TPMS technology).
• Employed in silico methods to estimate molecular mechanisms of action.
• Validated findings using an in vitro model of ALS with cultured spinal cord slices.

Main Results:

• Identified Aliretinoin and Pranlukast as a potential neuroprotective combination for ALS.
• Identified Aliretinoin and Mefloquine as another potential neuroprotective combination for ALS.
• Validated that these combinations promote motor neuron neuroprotection and reduce microgliosis in vitro.

Conclusions:

• Aliretinoin combined with Pranlukast or Mefloquine demonstrates significant neuroprotective effects in an ALS model.
• These drug combinations offer a promising therapeutic strategy by targeting multiple ALS pathological pathways.
• Further research into these combinations could lead to effective treatments for Amyotrophic Lateral Sclerosis.